Hung‐Ming Lam
Impact in
-
- Diabetes Treatment and Management
- Diabetes Management and Research
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
-
- Prostate Cancer Treatment and Research 22
-
- Epigenetics and DNA Methylation 5
- Ubiquitin and proteasome pathways 3
- Co-authors
- Colm Morrissey (11 shared papers)Robert L. Vessella (10 shared papers)Cyrus R. Mehta (2 shared papers)Venu Menon (1 shared paper)Alfonso T. Perez (2 shared papers)William C. Cushman (2 shared papers)William B. White (2 shared papers)Faı̈ez Zannad (1 shared paper)
- Journals
- Blood (3 papers)Journal of Clinical Oncology (3 papers)Endocrinology (3 papers)Nature Communications (3 papers)Oncotarget (2 papers)
- Partner nations
- United StatesCanadaMacao
In The Last Decade
Hung‐Ming Lam
55 papers receiving 2.6k citations
Hung‐Ming Lam's Hit Papers
Peers
Comparison fields: 5 of 104
- Endocrinology, Diabetes and Metabolism 615
- Cancer Research 426
- Oncology 651
- Pulmonary and Respiratory Medicine 696
- Molecular Biology 948
Countries citing papers authored by Hung‐Ming Lam
This map shows the geographic impact of Hung‐Ming Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hung‐Ming Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hung‐Ming Lam more than expected).
Fields of papers citing papers by Hung‐Ming Lam
This network shows the impact of papers produced by Hung‐Ming Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hung‐Ming Lam. The network helps show where Hung‐Ming Lam may publish in the future.
Co-authors
The 25 scholars most cited alongside Hung‐Ming Lam, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Hit paper breakdown → | 2015 | 571 |
| 2 | 2015 | 269 | |
| 3 | 2017 | 188 | |
| 4 | 2015 | 129 | |
| 5 | 2010 | 123 | |
| 6 | 2004 | 113 | |
| 7 | 2011 | 97 | |
| 8 | 2014 | 81 | |
| 9 | 2019 | 72 | |
| 10 | 2015 | 67 | |
| 11 | 2018 | 65 | |
| 12 | 2022 | 62 | |
| 13 | 2012 | 52 | |
| 14 | 2015 | 49 | |
| 15 | 2014 | 46 | |
| 16 | 2015 | 46 | |
| 17 | 2011 | 44 | |
| 18 | 2016 | 41 | |
| 19 | 2012 | 38 | |
| 20 | 2019 | 34 |
About Hung‐Ming Lam
Hung‐Ming Lam is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Surgery and Cancer Research, having authored 58 papers that have together received 2.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (22 papers), Bladder and Urothelial Cancer Treatments (9 papers), Cancer Cells and Metastasis (7 papers), Estrogen and related hormone effects (7 papers), Epigenetics and DNA Methylation (5 papers), Hemoglobinopathies and Related Disorders (4 papers), Erythropoietin and Anemia Treatment (4 papers) and Ubiquitin and proteasome pathways (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (615 citations), Cancer Research (426 citations), Oncology (651 citations), Pulmonary and Respiratory Medicine (696 citations) and Molecular Biology (948 citations). Hung‐Ming Lam has collaborated with scholars based in United States, Canada and Macao. Frequent co-authors include Colm Morrissey, Robert L. Vessella, Cyrus R. Mehta, Venu Menon, Alfonso T. Perez, William C. Cushman, William B. White, Faı̈ez Zannad, George L. Bakris and P. Fleck. Their work appears in journals such as Blood, Journal of Clinical Oncology, Endocrinology, Nature Communications and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.